OXFORD, England, February 15, 2018 /PRNewswire/ --
Oxford BioMedica plc (LSE:OXB) ("Oxford BioMedica" or "the
Group"), a leading gene and cell therapy group, today announces
that it has completed a major new collaboration & licence
agreement with Bioverativ Inc. for the development and
manufacturing of lentiviral vectors to treat haemophilia. The
agreement includes a licence to use OXB's LentiVector Enabled
technology and access to its industrial-scale manufacturing
technology.
Under the terms of the agreement, Oxford BioMedica will receive
a $5 million upfront payment from
Bioverativ. Oxford BioMedica is also eligible to receive various
milestone payments, potentially worth in excess of $100 million, and undisclosed royalties on net
sales of Bioverativ's lentiviral vector haemophilia products.
Bioverativ will also fund process development and scale-up
activities for its lentiviral vector haemophilia products at Oxford
BioMedica. The agreement also allows for the parties to put in
place a clinical supply agreement for GMP manufacturing of
haemophilia products at Oxford BioMedica.
Commenting on the announcement,
John Dawson, Chief Executive
Officer of Oxford BioMedica, said:
"Today's news demonstrates the value
of our LentiVector Enabled platform and our
leading capabilities and reputation in the industrial scale-up for
lentiviral vectors for clinical and commercial supply.
Bioverativ's investment in haemophilia
gene therapy underlines the potential of lentiviral vectors for
use for in vivo gene therapy. This new deal,
potentially worth in excess of $100m, demonstrates
Oxford BioMedica's strategy of
building multiple partnerships with leaders in
their therapeutic categories and will support the
Group's continued growth. Oxford
BioMedica is recognised as a world leader in the field of
development and manufacturing of lentiviral vectors and
we are delighted to be supporting Bioverativ
in the development of gene therapy products to
treat haemophilia."
The information contained within this announcement is deemed
by the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Notes to editors
About Oxford
BioMedica®
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
company focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector®) through which the Group develops in
vivo and ex-vivo products both in-house and with
partners. The Group has created a valuable proprietary portfolio of
gene and cell therapy product candidates in the areas of oncology,
ophthalmology and CNS disorders. The Group has also entered into a
number of partnerships, including with Novartis, Sanofi, GSK,
Bioverativ, GC LabCell and Immune Design, through which it has
long-term economic interests in other potential gene and cell
therapy products. Oxford BioMedica is based across several
locations in Oxfordshire, UK and
employs more than 300 people. Further information is available at
http://www.oxfordbiomedica.co.uk.
For further information, please contact:
Oxford BioMedica plc:
John Dawson, Chief Executive
Officer
Stuart Paynter, Chief Financial
Officer
Tel: +44(0)1865-783-000
Financial and corporate communications enquiries:
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal/Philippa
Gardner/Laura Thornton
Tel: +44(0)20-3709-5700
Peel Hunt (Joint Corporate Brokers):
James Steel
Christopher Golden
Tel: +44(0)20-7418-8900
WG Partners (Joint Corporate Brokers):
David Wilson
Claes Spang
Tel: +44(0)20-3705-9321
SOURCE Oxford BioMedica plc